CX NEWS
CX ilegx Collaboration Day addresses proactive approach to treat diabetic foot
With the aim to promote the best possible care of the ischaemic lower limb to reduce the number of major amputations, the CX ilegx Collaboration Day will offer delegates an overview of the latest treatment [...]
Mini-symposium explores false lumen challenges in acute and chronic type B dissection
Type B dissection. It is accepted that the prognosis and outcomes of type B dissection are more favourable if the false lumen is thrombosed. According to Roger Greenhalgh, chairman of the CX Programme [...]
IPD meta-analysis to show “highest level of evidence” for EVAR vs. open repair
Principal investigators: Roger Greenhalgh, Jan Blankensteijn, Jean-Pierre Becquemin and Frank Lederle. An Individual Patient Data (IPD) meta-analysis of the randomised controlled trials—EVAR 1, DREAM, ACE and OVER—will show the “highest level of evidence” [...]
Longest follow-up for EVAR to be presented for the first time at CX 2016
Roger Greenhalgh. Fifteen-year follow-up of the Endovascular Aneurysm Repair (EVAR) 1 Trial will be presented for the first time at CX 2016. The EVAR 1 Trial was the first EVAR vs. open repair [...]
Interview with Michel Makaroun at CX 2015
Interview with Michel Makaroun at CX 2015